Aquestive Therapeutics, Inc. (AQST) Insider Trading Activity
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
AQST Insider Trading Activity
AQST Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $214 | 1 | 100 |
Related Transactions
| Jung Cassie | Chief Operating Officer | 0 | $0 | 1 | $214 | $-214 |
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Insider Activity of Aquestive Therapeutics, Inc.
Over the last 12 months, insiders at Aquestive Therapeutics, Inc. have bought $0 and sold $214 worth of Aquestive Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Aquestive Therapeutics, Inc. have bought $63,498 and sold $488,639 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $4,050 was made by Boyd Peter E. (SVP‑Bus. Process & Info. Tech.) on 2022‑06‑14.
List of Insider Buy and Sell Transactions, Aquestive Therapeutics, Inc.
| 2024-11-26 | Sale | Jung Cassie | Chief Operating Officer | 44 <0.0001% | $4.87 | $214 | -38.11% | |
| 2024-03-15 | Sale | Schobel Alexander Mark | Chief Innovation/Tech Officer | 50,000 0.0672% | $6.00 | $300,000 | -40.23% | |
| 2024-03-08 | Sale | Schobel Alexander Mark | Chief Innovation/Tech Officer | 25,000 0.0364% | $5.19 | $129,685 | -23.36% | |
| 2022-06-14 | Boyd Peter E. | SVP-Bus. Process & Info. Tech. | 5,000 0.0107% | $0.81 | $4,050 | +11.38% | ||
| 2022-06-08 | Schobel Alexander Mark | Chief Innovation/Tech Officer | 45,871 0.1074% | $0.96 | $44,036 | +2.89% | ||
| 2022-06-08 | Boyd Peter E. | SVP-Bus. Process & Info. Tech. | 2,293 0.0054% | $0.96 | $2,201 | +2.89% | ||
| 2022-06-08 | BRAENDER LORI J | General Counsel | 13,761 0.0322% | $0.96 | $13,211 | +2.89% | ||
| 2021-02-10 | Sale | Schobel Alexander Mark | 23,460 0.0662% | $6.75 | $158,355 | -38.78% | ||
| 2021-02-09 | Sale | Schobel Alexander Mark | 11,540 0.0328% | $6.75 | $77,895 | -38.02% | ||
| 2021-02-08 | Sale | Schobel Alexander Mark | 40,792 0.1131% | $6.50 | $265,148 | -37.03% | ||
| 2020-08-18 | Sale | Maxwell John T. | 3,000 0.0088% | $8.00 | $24,000 | -37.84% | ||
| 2020-06-04 | Sale | Kendall Keith J | 100,000 0.2958% | $5.11 | $510,620 | +2.92% | ||
| 2020-05-08 | Sale | Schobel Alexander Mark | 80,000 0.2312% | $5.00 | $400,000 | +3.69% | ||
| 2020-04-29 | Sale | Schobel Alexander Mark | 80,000 0.2256% | $4.50 | $360,000 | +12.42% | ||
| 2020-04-27 | Sale | Schobel Alexander Mark | 80,000 0.229% | $4.00 | $320,000 | +28.37% | ||
| 2020-04-14 | Sale | Schobel Alexander Mark | 80,000 0.2445% | $3.85 | $308,000 | +42.40% | ||
| 2020-03-16 | Boyd Peter E. | 4,000 0.0058% | $0.75 | $3,000 | +246.43% | |||
| 2020-03-16 | BRAENDER LORI J | 28,000 0.0837% | $1.54 | $43,249 | +246.43% | |||
| 2019-08-27 | Barber Daniel | 4,000 0.0166% | $3.99 | $15,960 | +14.36% | |||
| 2019-08-21 | Scibetta James S | 1,800 0.0068% | $3.81 | $6,858 | +7.92% |
Insider Historical Profitability
| Jung Cassie | Chief Operating Officer | 0 0% | $0 | 0 | 1 | |
| Schobel Alexander Mark | Chief Innovation/Tech Officer | 984476 0.9912% | $2.25M | 4 | 9 | <0.0001% |
| Kendall Keith J | 638964 0.6433% | $1.46M | 6 | 1 | <0.0001% | |
| BRATTON DOUGLAS K | 165000 0.1661% | $377,850.00 | 1 | 0 | <0.0001% | |
| Maxwell John T. | 150614 0.1516% | $344,906.06 | 2 | 1 | <0.0001% | |
| Barber Daniel | 101959 0.1027% | $233,486.11 | 2 | 0 | <0.0001% | |
| Wood Theresa | 80765 0.0813% | $184,951.85 | 2 | 0 | <0.0001% | |
| Boyd Peter E. | SVP-Bus. Process & Info. Tech. | 59532 0.0599% | $136,328.28 | 5 | 0 | +43.71% |
| BRAENDER LORI J | General Counsel | 38761 0.039% | $88,762.69 | 4 | 0 | +53.97% |
| Scibetta James S | 31635 0.0319% | $72,444.15 | 3 | 0 | +13.42% | |
| Marshall Ken W. | 1445 0.0015% | $3,309.05 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$2,051,022 | 1591 | -12.84% | $77.66M | |
$218,350,131 | 64 | 16.68% | $154.73M | |
$125,860,243 | 57 | -4.48% | $36.57M | |
$129,489,279 | 57 | 26.09% | $399.59M | |
$2,740,482 | 50 | 9.37% | $37.66M | |
$33,884,330 | 45 | 12.58% | $424.36M | |
$97,642,477 | 41 | -10.58% | $653.14M | |
Aquestive Therapeutics, Inc. (AQST) | $6,021,989 | 30 | -0.17% | $227.44M |
$423,174,478 | 29 | -7.58% | $22.45M | |
$6,506,230 | 27 | -16.20% | $786.25M | |
$17,389,773 | 25 | -6.03% | $360.19M | |
$1,507,654 | 22 | -23.16% | $95.7M | |
$25,034,841 | 20 | 9.38% | $110.71M | |
$758,061 | 9 | 60.03% | $146.12M | |
$1,683,154 | 8 | 46.59% | $454.53M | |
$179,515 | 7 | 1.51% | $319.15M | |
$543,932 | 6 | -22.03% | $730.53M | |
$103,523 | 3 | 9.40% | $58.3M | |
$5,003,136 | 1 | -14.58% | $257.33M |
AQST Institutional Investors: Active Positions
| Increased Positions | 67 | +51.15% | 4M | +7.97% |
| Decreased Positions | 56 | -42.75% | 9M | -18.21% |
| New Positions | 22 | New | 851,145 | New |
| Sold Out Positions | 19 | Sold Out | 2M | Sold Out |
| Total Postitions | 142 | +8.4% | 43M | -10.24% |
AQST Ownership Change vs Market
Institutional Investor Ownership
| Bratton Capital Management, L.P. | $29,433.00 | 9.91% | 9.81M | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $17,807.00 | 6% | 5.94M | -62,844 | -1.05% | 2025-03-31 |
| Vanguard Group Inc | $13,040.00 | 4.39% | 4.35M | +82,958 | +1.95% | 2024-12-31 |
| Vr Adviser, Llc | $7,889.00 | 2.66% | 2.63M | -3M | -52.66% | 2024-12-31 |
| Franklin Resources Inc | $6,404.00 | 2.16% | 2.13M | -631,746 | -22.84% | 2024-12-31 |
| Geode Capital Management, Llc | $4,964.00 | 1.67% | 1.65M | -12,919 | -0.78% | 2024-12-31 |
| Mpm Bioimpact Llc | $4,835.00 | 1.63% | 1.61M | -184,917 | -10.29% | 2024-12-31 |
| State Street Corp | $4,512.00 | 1.52% | 1.5M | +7,152 | +0.48% | 2024-12-31 |
| Janney Montgomery Scott Llc | $3,179.00 | 1.07% | 1.06M | +75,275 | +7.65% | 2025-03-31 |
| Blue Owl Capital Holdings Lp | $2,700.00 | 0.91% | 900,000 | -325,000 | -26.53% | 2024-12-31 |